newsfilter
← Earnings
Earnings Releases·

Invivyd — Third Quarter 2026 Earnings Summary

Invivyd reported third-quarter 2026 net product revenue of $15.4 million for PEMGARDA, an 18% increase from the prior year period. The company announced positive topline results from its LIBERTY Phase 3 trial, demonstrating that VYD2311 has superior safety and tolerability compared to an mRNA COVID-19 vaccine without interfering with vaccine-induced antibodies. Additionally, Invivyd initiated the FLINTLOCK Phase 2 trial to evaluate VYD2311 for Long COVID and Post-Vaccination Syndrome while preparing for an imminent interim analysis of the DECLARATION Phase 3 trial data. Financially, the company recorded a net loss of $33.5 million for the quarter and ended with $126.4 million in cash and cash equivalents.

Company
INVIVYD INC
Sector
Healthcare
Industry
Biotechnology